Company profile
Harrow Health, Inc.
NASDAQ: HROW · Healthcare · Drug Manufacturers - Specialty & Generic
#259 of 1,418 Healthcare companies by revenue74th-percentile growth
EA Score
73BFH 71DQ 72GM 79SS 79
v0.1 · 65/100 weight · provisional
↑ operating margin, market scale · ↓ balance-sheet leverage, filing timeliness
Methodology →Revenue TTM
$268.7M
Rev growth YoY (TTM)
+26.2%
Net income (FY)
-$5.1M
Employees
373
as of 2026-08-09
Market cap
$1.5B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$272.3M$272.3M2025
Net income-$5.1M-$5.1M2025
Operating income$30.5M$30.5M2025
Total assets$399.5M$399.5M2025
Liabilities$347.4M$347.4M2025
Equity$52.4M$52.4M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product Sales Net100%
Other Revenues0%
By geography
Not disclosed.
The read
What is Harrow Health, Inc.’s revenue?
Harrow Health, Inc. booked $272.3M in FY2025 revenue, growing 36% year over year — faster than most Healthcare companies we track, at a -1.9% net margin.
Peers · Healthcare
Aurinia Pharmaceuticals Inc.78B+Adaptive Biotechnologies Corporation68BVericel Corporation83B+Viemed Healthcare, Inc.75B+Vireo Growth Inc.59CLigand Pharmaceuticals Incorporated80B+Neighbors
Davidson →Key facts
CEOMark L. Baum
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersNashville, TN
ExchangeNASDAQ: HROW
Employees373
IPO date2007-09-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.